Abstract:Objective: The intent of this study was to examine the recovery of individuals who had been hospitalized for severe acute respiratory syndrome (SARS) in the year following their discharge from the hospital. Parameters studied included serum levels of SARS coronavirus (SARS-CoV) IgG antibody, tests of lung function, and imaging data to evaluate changes in lung fibrosis. In addition, we explored the incidence of femoral head necrosis in some of the individuals recovering from SARS.
Methods:The subjects of this s… Show more
“…The serial results suggest an increase of the intra-alveolar diffusion pathway, which might be the result of diffuse alveolar damage and/or BOOP initially, 38 -41 followed by postinflammatory changes such as atelectasis, ongoing alveolitis, and parenchymal fibrosis later in the course of the disease. Our results are similar to a long-term follow-up study 44 in Beijing that reported that 27.3% of their SARS survivors (85 of 311 patients) had impaired Dlco, whereas 21.5% exhibited radiographic evidence of lung fibrotic changes at 1 year. Several studies [45][46][47] on ARDS survivors have shown that their pulmonary function generally returns to normal or near normal by 6 to 12 months, but Dlco may remain abnormal in up to 80% of patients at 1 year after recovery.…”
Significant impairment in Dlco was noted in 23.7% of survivors 1 year after illness onset. Exercise capacity and health status of SARS survivors were remarkably lower than those of a normal population.
“…The serial results suggest an increase of the intra-alveolar diffusion pathway, which might be the result of diffuse alveolar damage and/or BOOP initially, 38 -41 followed by postinflammatory changes such as atelectasis, ongoing alveolitis, and parenchymal fibrosis later in the course of the disease. Our results are similar to a long-term follow-up study 44 in Beijing that reported that 27.3% of their SARS survivors (85 of 311 patients) had impaired Dlco, whereas 21.5% exhibited radiographic evidence of lung fibrotic changes at 1 year. Several studies [45][46][47] on ARDS survivors have shown that their pulmonary function generally returns to normal or near normal by 6 to 12 months, but Dlco may remain abnormal in up to 80% of patients at 1 year after recovery.…”
Significant impairment in Dlco was noted in 23.7% of survivors 1 year after illness onset. Exercise capacity and health status of SARS survivors were remarkably lower than those of a normal population.
“…19 In survivors of severe acute respiratory syndrome (SARS) followed for 1 year, marked improvements in pulmonary fi brosis have been seen, but some patients still had residual changes. 20 Because this kind of fi brosis was reversible, it has been suggested that these fi ndings were partially caused by postinflammatory atelectasis rather than by genuine fi brosis alone. 21 The resolution of lung abnormalities in patients with A(H1N1) viral pneumonia seemed better than that seen in patients with SARS and infl uenza A(H5N1) infection.…”
“…[4][5][6][7][8] As SARS is a disease that has recently emerged, the long-term sequelae are largely unclear. Studies on the lung function outcome of SARS survivors have been reported; [9][10][11][12][13][14][15][16][17][18][19] however, the longest duration of follow up was around 3 years and small numbers of subjects were studied. 18,19 We have previously reported the 6 month 12 and 1 year outcomes 13 from the Prince of Wales Hospital SARS patient cohort, based on the available normative lung function data collected in the 1960s.…”
This 2-year study of a selected population of SARS survivors, showed significant impairment of DL(CO), exercise capacity and health status persisted, with a more marked adverse impact among HCW.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.